Diabetic retinopathy (DR) is a leading cause of vision loss in working-age Americans. Capillary damage from hyperglycemia causes vision loss through downstream effects, such as retinal ischemia, edema, and neovascularization (NV). Proper screening and timely treatment with laser photocoagulation and anti-vascular endothelial growth factor (VEGF) injections can minimize morbidity. In the last decade, clinicians have been able to use objective structural data from optical coherence tomography (OCT) to guide the treatment of diabetic macular edema. Other aspects of care, however, still largely depend on subjective interpretation of clinical features and fluorescein angiography (FA) to determine the disease severity and treatment threshold. The recently developed OCT angiography (OCTA) provides dye-less, injection-free, three-dimensional images of the retinal and choroidal circulation with high capillary contrast. Not only is it safer, faster, and less expensive than conventional dye-based angiography, OCTA provides the potential of giving clinicians objective tools for determining severity of disease by detecting and quantifying NV and non-perfusion.
Study Type
OBSERVATIONAL
Enrollment
290
Oregon Health & Science University
Portland, Oregon, United States
PR-OCTA Measure of Non-Perfusion Areas
Non-perfusion areas of the 3 retinal plexuses and choriocapillaris will be measured in mm2.
Time frame: 3 years
Non-PR-OCTA Measure of Retinal Non-Perfusion Areas
Non-perfusion areas of the 3 retinal plexuses will be measured in mm2.
Time frame: 1 year
Non-PR-OCTA Retinal Neovascularization Areas
Retinal neovascularization areas will be measured in mm2.
Time frame: 1 year
Structural OCT Cyst Volume
Cyst volume will be measured in mm3.
Time frame: 1 year
Structural OCT Retinal Thickening Area
The area of retinal thickening will be measured in mm2.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.